HMGB1 and amyotrophic lateral sclerosis: Therefore, the circulating levels of eosinophil-derived neurotoxin, eotaxin, granzyme A and granzyme B, high mobility group box 1 (HMGB1) autoantibody, interleukin-6, interferon-γ, monocyte chemoattractant protein-1 (MCP-1), tumor necrosis factor-α (TNF-α), tumor necrosis factor receptor, and wide-range C-reactive protein (wrCRP) were found to be increased in ALS patients [48–51, 57–63, 67].